Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ligand Pharmaceuticals (LGND) Change in Acquisitions & Divestments: 2009-2024

Historic Change in Acquisitions & Divestments for Ligand Pharmaceuticals (LGND) over the last 15 years, with Dec 2024 value amounting to $229.4 million.

  • Ligand Pharmaceuticals' Change in Acquisitions & Divestments fell 41.22% to $53.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $176.3 million, marking a year-over-year decrease of 27.15%. This contributed to the annual value of $229.4 million for FY2024, which is 54.18% up from last year.
  • Per Ligand Pharmaceuticals' latest filing, its Change in Acquisitions & Divestments stood at $229.4 million for FY2024, which was up 54.18% from $148.8 million recorded in FY2023.
  • Ligand Pharmaceuticals' 5-year Change in Acquisitions & Divestments high stood at $644.2 million for FY2020, and its period low was $148.8 million during FY2023.
  • Its 3-year average for Change in Acquisitions & Divestments is $195.9 million, with a median of $209.6 million in 2022.
  • Per our database at Business Quant, Ligand Pharmaceuticals' Change in Acquisitions & Divestments crashed by 76.06% in 2021 and then skyrocketed by 54.18% in 2024.
  • Over the past 5 years, Ligand Pharmaceuticals' Change in Acquisitions & Divestments (Yearly) stood at $644.2 million in 2020, then slumped by 76.06% to $154.2 million in 2021, then soared by 35.88% to $209.6 million in 2022, then decreased by 29.01% to $148.8 million in 2023, then spiked by 54.18% to $229.4 million in 2024.